Related Experiment Video
Updated: Jun 21, 2025
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.3K
"Cardiac glycosides"-quo vaditis?-past, present, and future?
Julia Fender1, Johanna Klöcker1, Valérie Boivin-Jahns1
1Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Straße 9, 97078, Würzburg, Germany.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|July 15, 2024
Summary
Digitalis glycosides, or cardiac glycosides, inhibit Na+/K+-ATPase and are used for heart failure and atrial fibrillation. This review covers their history, research, and debated pros and cons.
Area of Science:
- Pharmacology
- Cardiology
- Medical History
Background:
- Digitalis glycosides, also known as cardiac glycosides, are established Na+/K+-ATPase inhibitors.
- These drugs have a long history in treating heart failure and atrial fibrillation.
- Despite their use, they possess a narrow therapeutic range and ongoing debate regarding their indications.
Purpose of the Study:
- To review the historical context of digitalis glycosides.
- To summarize key findings from basic and clinical research.
- To discuss the overlooked advantages and disadvantages of these cardiac glycosides.
Main Methods:
- Literature review of historical data.
- Synthesis of findings from basic science research.
- Analysis of clinical trial outcomes and patient data.
Main Results:
- Detailed historical progression of digitalis glycoside use.
- Summary of fundamental mechanisms of action and clinical effects.
- Identification and discussion of both beneficial and detrimental aspects, including safety profiles.
Conclusions:
- Cardiac glycosides remain relevant therapeutic agents with a complex benefit-risk profile.
- Further research and careful patient selection are crucial for optimizing their use.
- Understanding their full spectrum of pros and cons is essential for modern clinical practice.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733
01:16Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336